Cong Xu, M.D., Ph.D., is a Principal with Lilly Asia Ventures (LAV). Prior to joining LAV, Cong worked for Eli Lilly and Company as medical director(associate) in oncology, leading regional clinical development for a number of oncology molecules including blockbuster abemaciclib. Prior to that, he was a US Board certified physician. Cong holds a Ph.D. in biology from Clemson University, US, an M.B.A. from University of British Columbia, Canada, and M.D. from Tongji Medical College, China.